Illumina, Inc. vs Manulife Financial Corporation — how do they compare? Illumina, Inc. trades at $271.25 (market cap $39.95B), while Manulife Financial Corporation trades at $42.32 (market cap $69.48B). The key difference: Manulife Financial Corporation is the larger of the two by market cap, and Manulife Financial Corporation pays a 3.23% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Manulife Financial Corporation for 119 Days on average.
| ILMN | MFC | |
|---|---|---|
Market Cap | $39.95B | $69.48B |
Volume | 3,169,503 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $293.69 | $44.77 |
52-Week Low | $91.00 | $31.64 |
Typical Hold Time | 83 Days | 119 Days |
Enterprise Value | $41.31B | $64.75B |
Dividend Yield | — | 3.23% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Manulife Financial (MFC) trades at $41.67, down 2.94% on the day, with a bearish technical signal from moving averages and oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B and a P/E of 16.22. Recent news includes a new $750M subordinated notes offering and executive appointments, while institutional investors like Bank of America added positions in Q2 2026.
The outlook is mixed: analyst consensus is Buy with a $34.24 target, but technicals suggest near-term pressure. Upside drivers include strong insurance sales and Asia growth, while risks involve premium valuation and macroeconomic sensitivity. Cash flow trends show improved operations, but net cash flow declined in 2025.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →